Orchard Therapeutics hits up Hitachi CDMO to make autologous gene therapy – BioPharma-Reporter.com
|
Orchard Therapeutics hits up Hitachi CDMO to make autologous gene therapy
BioPharma-Reporter.com Under terms of the deal, PCT will make clinical supplies of OTL-101, an autologous ex-vivo gene therapy for the treatment of adenosine deaminase deficiency severe combined immunodeficiency (ADA-SCID). The Manufacturing Services Agreement (MSA) is … |
